Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 182 of the 182 references it cites were found in a registry or an index.

Nanocarrier-based targeted drug delivery for Alzheimer’s disease: addressing neuroinflammation and enhancing clinical translation

Open access
Wang, Kang, Yang, Rongying, Li, Jing, Wang, Haitao, Wan, Li, He, Jiale · 2025 · Frontiers in Pharmacology

Abstract

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, amyloid-beta (Aβ) aggregation, tau pathology, and chronic neuroinflammation. Among these, neuroinflammation plays a crucial role in exacerbating disease progression, making it an attractive therapeutic target. However, the presence of the blood-brain barrier (BBB) significantly limits the effective delivery of therapeutic agents to the brain, necessitating novel drug delivery strategies. Nanocarrier-based delivery systems have emerged as a promising solution to these challenges, offering targeted drug transport, enhanced BBB penetration, and improved bioavailability while minimizing systemic toxicity. This review explores the current advancements in nanocarrier-mediated drug delivery for AD, focusing on the mechanisms of neuroinflammation, the role of nanocarriers in overcoming the BBB, and their ability to modulate inflammatory pathways. Furthermore, the review discusses preclinical validation strategies and key challenges, including safety concerns, large-scale production limitations, and regulatory hurdles that must be addressed to enable clinical translation. Future perspectives emphasize the integration of nanotechnology with precision medicine, gene therapy, and artificial intelligence to optimize nanocarrier design for individualized AD treatment. By overcoming these obstacles, nanocarriers hold the potential to revolutionize therapeutic approaches for AD and other neurodegenerative diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fphar.2025.1591438

Cites

182 of 182 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIGURE 1 A schematic diagram of brain and simple longitudinal zoom in blood brain barrier (Created by BioRender). Extracted from author Abeer Alahmari (Alahmari, 2021). Copyright © 2021 Abeer Alahmari.
FIGURE 1 A schematic diagram of brain and simple longitudinal zoom in blood brain barrier (Created by BioRender). Extracted from author Abeer Alahmari (Alahmari, 2021). Copyright © 2021 Abeer Alahmari.CC BY · PubMed Central
FIGURE 2 Interconnections among microglia, Aβ, tau, and neurons. In their early developmental stages, microglia enhance the phagocytic capacity and generate phagocytoma abnormal material, such as cell debris and misfolded proteins. Subsequently, M2 microglial cells are promoted to release proinflammatory mediators, leading to an inflammatory storm. In this process, the amyloid monomers gradually accumulated to form amyloid plaques. Meanwhile, free tau proteins are phosphorylated and aggregated in neurons to form neurofibrillary tangles. The accumulation of Aβ plaques and the formation of neurofibrillary tangles could positively feedback to microglia to promote the activation of microglia, leading to impaired ability to phagosome foreign objects. Extracted from author Wang et al. (Wang et al., 2023). Copyright © 2023 Wang, Zong, Cui, Wang, Wu, Wang, Liu and Lu.
FIGURE 2 Interconnections among microglia, Aβ, tau, and neurons. In their early developmental stages, microglia enhance the phagocytic capacity and generate phagocytoma abnormal material, such as cell debris and misfolded proteins. Subsequently, M2 microglial cells are promoted to release proinflammatory mediators, leading to an inflammatory storm. In this process, the amyloid monomers gradually accumulated to form amyloid plaques. Meanwhile, free tau proteins are phosphorylated and aggregated in neurons to form neurofibrillary tangles. The accumulation of Aβ plaques and the formation of neurofibrillary tangles could positively feedback to microglia to promote the activation of microglia, leading to impaired ability to phagosome foreign objects. Extracted from author Wang et al. (Wang et al., 2023). Copyright © 2023 Wang, Zong, Cui, Wang, Wu, Wang, Liu and Lu.CC BY · PubMed Central
FIGURE 3 Main pathways for nano systems to cross blood-brain barrier. (A) Therapeutic ligands enabling active transport at the blood-brain barrier (BBB) can be conjugated to a nanoparticle, and then transported into the BBB. (B) A schematic presentation of various pathways of NPs crossing the BBB toward the brain: 1) Para cellular pathway, 2) transcellular pathway, 3) transcytosis, and 4) receptor mediated endocytosis. Extracted from author Saeedi et al. (2019). © 2018 Elsevier Masson SAS.
FIGURE 3 Main pathways for nano systems to cross blood-brain barrier. (A) Therapeutic ligands enabling active transport at the blood-brain barrier (BBB) can be conjugated to a nanoparticle, and then transported into the BBB. (B) A schematic presentation of various pathways of NPs crossing the BBB toward the brain: 1) Para cellular pathway, 2) transcellular pathway, 3) transcytosis, and 4) receptor mediated endocytosis. Extracted from author Saeedi et al. (2019). © 2018 Elsevier Masson SAS.CC BY · PubMed Central
FIGURE 4 Schematic representation of the structures of the most commonly used nanomedicine types for Alzheimer’s disease: lipid (liposomes and solid lipid), organic (dendritic and polymer), inorganic (metal and non-metal inorganic) and biomimetic (albumin). Extracted from author Hu L. et al. (2023). Copyright © 2023 Hu, Tao, Jiang and Qin.
FIGURE 4 Schematic representation of the structures of the most commonly used nanomedicine types for Alzheimer’s disease: lipid (liposomes and solid lipid), organic (dendritic and polymer), inorganic (metal and non-metal inorganic) and biomimetic (albumin). Extracted from author Hu L. et al. (2023). Copyright © 2023 Hu, Tao, Jiang and Qin.CC BY · PubMed Central
FIGURE 5 Using focused ultrasound to open the blood-brain barrier allows for the passage of drug molecules. Extracted from author Lipsman et al. (2018). © 2019 Elsevier B.V. All rights reserved.
FIGURE 5 Using focused ultrasound to open the blood-brain barrier allows for the passage of drug molecules. Extracted from author Lipsman et al. (2018). © 2019 Elsevier B.V. All rights reserved.CC BY · PubMed Central
FIGURE 6 Cellular internalization of fluorescently labeled micelles and core-loaded hydrophobic probes inspected by confocal fluorescence microscopy. (A,B) KB cells treated with 0.2 mg/mL dual-labeled micelles for 24 h. The green color represents the FITC signal from labeled micelles, and the red color represents the DiI signal. (Inset) Diagram of a micelle labeled with FITC and loaded with DiI. (C) KB cells incubated with free DiI in DMSO at the final concentration of 0.1 μg/mL for 24 h. (D) HeLa cells incubated with 0.2 mg/mL micelles (physically loaded with 0.15% DiI) for 2 h. DiI was accumulated in the microtubule organizing center area. Extracted from author Chen et al. (2008). © 2008 by The National Academy of Sciences of the USA.
FIGURE 6 Cellular internalization of fluorescently labeled micelles and core-loaded hydrophobic probes inspected by confocal fluorescence microscopy. (A,B) KB cells treated with 0.2 mg/mL dual-labeled micelles for 24 h. The green color represents the FITC signal from labeled micelles, and the red color represents the DiI signal. (Inset) Diagram of a micelle labeled with FITC and loaded with DiI. (C) KB cells incubated with free DiI in DMSO at the final concentration of 0.1 μg/mL for 24 h. (D) HeLa cells incubated with 0.2 mg/mL micelles (physically loaded with 0.15% DiI) for 2 h. DiI was accumulated in the microtubule organizing center area. Extracted from author Chen et al. (2008). © 2008 by The National Academy of Sciences of the USA.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 182 references

Cited by

See all 27

Metadata

Authors
Wang, K., Yang, R., Li, J., Wang, H., Wan, L., & He, J.
Affiliations
  • Southwest Medical University (CN)
  • Sheng Jing Hospital (CN)
  • First Hospital of China Medical University (CN)
  • China Academy of Chinese Medical Sciences (CN)
Corresponding author
He, Jiale
Venue
Frontiers in Pharmacology
Published
2025-05-14
Volume
16
Pages
1591438-1591438
ISSN
1663-9812 (ISSN-L)
OpenAlex
W4410380802
Cited by
27
References
182
Citations by year
2026: 23 · 2025: 4
FWCI
1.56
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Pharmacology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
Keywords
Alzheimer's disease, nanocarriers, targeted drug delivery, neuroinflammation, blood-brain barrier, amyloid-beta, tau pathology, blood-brain barrier penetration, inflammatory signaling, clinical translation, nanocarrier safety, regulatory challenges, precision medicine, gene therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Nanocarrier-based targeted drug delivery for Alzheimer’s disease: addressing neuroinflammation and enhancing clinical translation. https://app.cochat.ai/papers/10.3389/fphar.2025.1591438
The paper
Wang, K., Yang, R., Li, J., Wang, H., Wan, L., & He, J. (2025). Nanocarrier-based targeted drug delivery for Alzheimer’s disease: addressing neuroinflammation and enhancing clinical translation. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2025.1591438

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.